DALTEPARIN VERSUS ASPIRIN IN RECENT-ONSET CENTRAL RETINAL VEIN OCCLUSION

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

FARAHVASH M.S.; MOGHIMI S.; ALAMI HARANDI Z.; KARKHANEH R.

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CURRENT OPHTHALMOLOGY Year:2004 | Volume:16 | Issue:3 Page(s): 44-49

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

1,199

Download:

Cites:

Information Journal Paper

Title

DALTEPARIN VERSUS ASPIRIN IN RECENT-ONSET CENTRAL RETINAL VEIN OCCLUSION

Author(s)

FARAHVASH M.S. | MOGHIMI S. | ALAMI HARANDI Z. | KARKHANEH R. | Issue Writer Certificate

Keywords

CRVOQ4

LMWHQ4

HEPARINQ4

DALTEPARINQ4

NEOVASCULARIZATIONQ4

Abstract

Purpose: To compare the effect of DALTEPARIN (Low molecular weight HEPARIN) versus Aspirin on recent-onset central retinal vein occlusion (CRVO). Patients & Methods: A randomized controlled clinical trial was conducted on patients with definite CRVO of less than 21 days duration. Patients in the DALTEPARIN group received subcutaneous DALTEPARIN (100 IU/kg bid for 10 days and 100 IU/kg daily for another 10 days); patients in the aspirin group were given Aspirin (100 mg daily). Results: Thirty-eight patients were enrolled, 18 in the DALTEPARIN group and 20 in the Aspirin group. The duration of follow-up was 6 months. Visual outcome was compared between two groups and no significant difference was found (P=0.74). All 3 patients who received DALTEPARIN within 7 days of onset of CRVO had dramatic improvement in visual acuity (mean change in logMAR=1.16). NVI occurred significantly less frequently in DALTEPARIN treated cases as compared with Aspirin (0.55% vs. 30%, P=0.006). Conclusion: Patients treated with DALTEPARIN within 21 days of onset of CRVO were less likely to develop NVI. There was no significant difference in visual acuity between the two groups at 6 months.

Cites

No record.

References

No record.

Cite

APA: Copy

FARAHVASH, M.S., MOGHIMI, S., ALAMI HARANDI, Z., & KARKHANEH, R.. (2004). DALTEPARIN VERSUS ASPIRIN IN RECENT-ONSET CENTRAL RETINAL VEIN OCCLUSION. JOURNAL OF CURRENT OPHTHALMOLOGY, 16(3), 44-49. SID. https://sid.ir/paper/53136/en

Vancouver: Copy

FARAHVASH M.S., MOGHIMI S., ALAMI HARANDI Z., KARKHANEH R.. DALTEPARIN VERSUS ASPIRIN IN RECENT-ONSET CENTRAL RETINAL VEIN OCCLUSION. JOURNAL OF CURRENT OPHTHALMOLOGY[Internet]. 2004;16(3):44-49. Available from: https://sid.ir/paper/53136/en

IEEE: Copy

M.S. FARAHVASH, S. MOGHIMI, Z. ALAMI HARANDI, and R. KARKHANEH, “DALTEPARIN VERSUS ASPIRIN IN RECENT-ONSET CENTRAL RETINAL VEIN OCCLUSION,” JOURNAL OF CURRENT OPHTHALMOLOGY, vol. 16, no. 3, pp. 44–49, 2004, [Online]. Available: https://sid.ir/paper/53136/en

Related Journal Papers